Given an abstract of a paper, generate a title for this paper such that conveys the key focus of the paper.

Abstract: The ability to breathe spontaneously through an endotracheal tube is a usual prerequisite before an intubated patient can have it removed. Other researchers have measured air flow resistance through endotracheal tubes. In this study, we evaluated work of breathing in joules per min and tension-time index while three normal volunteers breathed through different sized endotracheal tubes. Four 27.5-cm endotracheal tubes were used. Subjects breathed with a constant tidal volume of 500 ml. By increasing respiratory frequency, minute ventilation was increased from 5 to 30 L/min. As tube diameter decreased, work and the tension-time index increased. Changes were magnified at higher minute ventilations through the 6- and 7-mm endotracheal tubes, and the tension-time index critical fatigue level of 0.15 was approached or exceeded.
Work of breathing through different sized endotracheal tubes.

Abstract: Methods for endoscopic retrograde cholangiography (ERC) and endoscopic papillotomy (EPT) in patients with Billroth-II operations are described, and experience with their use during the last four years (since 1980) is presented. Endoscopic retrograde cholangiopancreatography was successful in 134 of 147 patients (92%) and endoscopic papillotomy was successful in 46 of 50 patients. The described methods were used in two different hospitals by two different endoscopists and there was no difference in the results. We conclude that patients with a Billroth-II operation may undergo endoscopic diagnostic as well as therapeutic procedures with a high rate of success, with similar results as in ordinary patients and with no greater risk of complications.
Endoscopic retrograde cholangiography and endoscopic papillotomy in patients with a previous Billroth-II resection.

Abstract: We conducted a randomized trial comparing a high (120 mg/m2 day 1) v a standard (60 mg/m2 day 1) dose of cisplatin in combination with etoposide (120 mg/m2 days 3, 5, and 7) in advanced non-small-cell lung carcinoma (NSCLC). Two hundred forty-one patients were evaluable for survival and 207 for response. We obtained a 25% objective response rate in the standard-dose arm and 29% in the high-dose arm; this difference was not statistically significant. There was no significant improvement in the overall survival or survival of responders with the high-dose regimen. However, toxicity (mainly myelosuppression) was significantly increased in the patients receiving the higher dose of cisplatin. An analysis of prognostic factors showed that disease progression, loss of body weight, performance status, and prior therapy were predictive parameters of survival.
A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma.